Latest Biotech News

Revolution Medicines reported phase 3 success for its investigational KRAS inhibitor daraxonrasib in metastatic pancreatic cancer, extending survival versus chemotherapy in a registrational...

Ideaya Biosciences reported that its uveal melanoma program cleared an internal success benchmark in a late-stage open-label trial. The company said the results strengthen expectations for an...

Allogene Therapeutics said its off-the-shelf CAR-T, cema-cel, achieved an interim goal in an ongoing phase 3 trial in B-cell lymphoma. In the interim analysis, 58% of treated patients reached...

GSK said it plans five phase 3 studies for an antibody-drug conjugate licensed from Hansoh Pharma after early promising data. The company’s move expands the late-stage footprint for a gynecologic...

Final overall survival results from the phase 3 ROSELLA trial showed that relacorilant plus nab-paclitaxel reduced the risk of death versus nab-paclitaxel alone in platinum-resistant ovarian...

Spyre Therapeutics reported early phase 2 results supporting its ulcerative colitis monoclonal antibody approach. In its SKYLINE study, subjects taking SPY001 met the primary safety goal and...

Sidewinder Therapeutics secured a $137 million Series B to advance a pipeline of bispecific antibody-drug conjugates targeting cancer. The funding is co-led by Frazier Life Sciences and the...

Labcorp and Children’s Hospital of Philadelphia (CHOP) announced plans to develop and commercialize specialty pediatric diagnostics. The collaboration is designed to move tests across areas...

AbbVie agreed to pay Chinese biotech Haisco $30 million upfront for two non-opioid acute pain candidates, part of a deal described at up to $745 million. The transaction expands AbbVie’s pain...

Regeneron entered radiopharmaceutical expansion through a $2.1 billion biobucks pact with Telix. The agreement ties into Regeneron’s shifting growth strategy as its obesity program activity and...

GSK is moving an antibody-drug conjugate licensed from Hansoh Pharma into an expanded late-stage development plan after early data signaled potential in gynecological cancers. The company said it...

Final overall survival data from the Phase 3 ROSELLA trial show that relacorilant (Lifyorli) added to nab-paclitaxel significantly improves outcomes in platinum-resistant ovarian cancer. At the...

Sidewinder Therapeutics and Stipple Bio announced large financing rounds aimed at improving the targeting capabilities of antibody-drug conjugates. Both startups said they are on track to enter...

Seaport Therapeutics’ peer Hemab is joined by Avalyn Pharma as the IPO market shows renewed activity, with Avalyn filing a registration statement to raise capital for respiratory treatments. The...

A mouse-model study published in Cell Death Discovery reports that long-term administration of the selective NMDA GluN2B antagonist Ro25-6981 attenuates neurodegeneration in spinocerebellar ataxia...

An author correction published by Sun, Schulte, Gasser, and colleagues in npj Parkinson’s Disease updates the refined genetic associations tied to Parkinson’s disease susceptibility. The...

A new study in npj Parkinson’s Disease describes a machine learning approach for identifying individuals with Parkinson’s disease who are at heightened risk of falling. The work presents a...

Researchers report that β2 adrenergic receptors help direct neutrophil behavior after myocardial infarction, identifying a mechanism that shapes cardiac immune responses during ischemic injury....

A preclinical-to-early translational development in reproductive medicine suggests securinine, a natural alkaloid, can boost small ovarian follicle growth when delivered via intraovarian...

A high-throughput strategy targeting MDM2 is presented as a potential way to overcome radiation resistance in uveal melanoma, a cancer where durable control remains difficult. The approach focuses...